Resistance to activated protein C. The most common cause of familial thrombophilia;Resistens mod aktiveret protein C: Den hyppigste årsag til familiær trombofili

Ugeskrift for Laeger

Volumn 158, Issue 46, 1996, Pages 6584-6588

  Larsen, Torben B ^a,b   Ravn, Hanne B ^a   Lassen, Jens F ^a   Lund, Erik D ^a   Brandslund, Ivan ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; PROTEIN C;

FEMALE; GENETICS; HUMAN; MALE; POINT MUTATION; PREGNANCY; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

ANTICOAGULANTS; FACTOR V; FEMALE; HUMANS; MALE; POINT MUTATION; PREGNANCY; PROTEIN C; RISK FACTORS; THROMBOEMBOLISM;

EID: 0030580203     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Nielsen HK, Lassen JF, Ravn HB, Husted SE. Antikoagulansbehandling og trombolyse ved dyb venøs trombose og lungeemboli. Ugeskr Læger 1995; 157: 2835-40.
2. Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent protein C and S of CB4-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-43.
3. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-8.
4. Tabernero MD, Tomas JF, Alberca I, Orfao A, Lopez Borrasca A, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-4.
5. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
6. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
7. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-22.
8. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
9. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
10. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A 1994; 91: 1396-400.
11. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
12. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
13. Dahlbäck B. Molecular genetics of venous thromboembolism. Ann Med 1995; 27: 187-92.
14. Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994; 24: 139-51.
15. Denson KWE, Reed SV, Haddon ME. The modified APC resistance test Thromb Haemost 1995; 74: 995
16. Dahlbäck B. Test för APC-resistens före P-pillerecept? Läkartidningen 1995; 92: 4558-60.
17. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]. Blood 1993; 82: 1989-93.
18. Gou D, Naipal A, Reitsma PH. World distribution af factor V Leiden mutation. Lancet 1996; 347: 59.
19. Takamiya O, Ishida F, Kodaira H, Kitano K. APC-resistance and Mnll genotype (Gln 506) of coagulation factor V are rare in the Japanese population. Thromb Haemost 1995; 74: 996.
20. De Maat MPM, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden mutation. Lancet 1996; 347: 58-9.
21. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
22. Zoller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
23. Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Kojima K, Hackeng TM et al. Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995; 74:444-8.
24. Weiss N. Third-generation oral contraceptives: how risky? Lancet 1995; 346: 1570
25. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1995; 346: 1575-82.
26. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
27. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
28. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
29. Østerud B, Robertsen R, Åsvang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 1994; 5: 853-4.
30. Vasse M, Leduc O, Borg JY, Chretien MH, Monconduit M. Resistance to activated protein C: evaluation of three functional assays. Thromb Res 1994; 76: 47-59.
31. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
32. Emmerich J, Poirier O, Evans A, Marques Vidal P, Arveiler D, Luc G et al. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance [letter]. Lancet 1995; 345: 321.
33. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
34. Siebler M, Nachtmann A, Sitzer M, Steinmetz H. Anticoagulation monitoring and cerebral microemboli detection [letter]. Lancet 1994; 344: 555.
35. Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction [letter]. Lancet 1995; 345: 795.
36. Bridey F, Wolff M, Laissy JP, Morin V, Lefebvre M, de Prost D. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost 1995; 74: 1382.
37. Faunø P, Ravn HB, Lassen JF, Lund ED, Jensen J. Association between activated protein C resistance and postoperative deep vein thrombosis? Thromb Haemost 1995; 73: 1371.
38. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797-8.
39. Koeleman BP, van Rumpt D, Hamulyák K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-3.
40. Keeling DM. Factor V: Q506 and a negative APC-resistance test. Thromb Haemost 1995; 74: 1380.